Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Brand name: Clopidogrel (AN) TM
Active ingredients: clopidogrel
On March 27, 2019 Clopidogrel (AN) was not listed on the Australian Register of Therapeutic Goods (ARTG).
Healthdirect medicine data is refreshed once a month, see Data sources page. The medicine you searched for may have been added to the ARTG after this date.
Ask your pharmacist, doctor or health professional for advice, or search the ARTG.
Is this medicine available in Australia?
The ARTG is the register of all therapeutic goods that can be lawfully supplied in Australia. Sometimes a special provision is made to make available some medicines that are not listed in response to the needs of particular people or circumstances. To find out more check out the "Access to therapeutic goods not on the ARTG" section on the ARTG page.
Other medicines that contain: clopidogrel
Need more information?
These trusted information partners have more on this topic.
Top results
Taking medications - ANZCA
Read more on ANZCA – Australian and New Zealand College of Anaesthetists website
Petechiae skin purpura information | myVMC
Petechiae skin purpura are pinpoint bleeds under the skin which may result from trauma, infection or in serious cases requiring treatment, a blood disorder.
Read more on myVMC – Virtual Medical Centre website
Renal biopsy
This medical procedure involves taking a small sample tissue (biopsy) from the kidney so that it can be examined under the microscope. It is usually done on the left kidney.
Read more on WA Health website
Ischaemic stroke information | myVMC
Ischaemic stroke occurs when there is insufficient blood flow to supply oxygen to the brain. It is a leading cause of death and disability.
Read more on myVMC – Virtual Medical Centre website
Angioplasty | myVMC
Medical information about angioplasty procedure for coronary (heart) patients. Angioplasty is heart operation medical treatment for coronary artery disease.
Read more on myVMC – Virtual Medical Centre website
Peripheral arterial disease - myDr.com.au
Peripheral arterial disease refers to a narrowing of the blood vessels in the legs. Find out about the symptoms, risk factors, tests and treatment.
Read more on myDr website
Carotid Stenting - InsideRadiology
InsideRadiology
Read more on InsideRadiology website
Biliary Drainage - InsideRadiology
InsideRadiology
Read more on InsideRadiology website
Pleural Aspiration - InsideRadiology
InsideRadiology
Read more on InsideRadiology website
Ascitic Tap - InsideRadiology
InsideRadiology
Read more on InsideRadiology website
Top results
Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease | Cochrane
Low-dose aspirin as antiplatelet therapy is still the drug of choice for preventing cardiovascular events, but the protection aspirin gives to people at high risk of cardiovascular events is only relatively modest. This review of 28,165 people in two trials where clopidogrel was given in addition to antiplatelet treatment found that in patients with acute coronary syndromes the benefit - a reduction in cardiovascular events - outweighs the harm of major bleeding. However, clopidogrel plus aspirin has no clear positive risk-benefit profile in people at high risk of cardiovascular events (multiple atherothrombotic risk factors) or in people with established cardiovascular disease (known coronary disease, ischemic cerebrovascular disease or peripheral arterial disease) but not presenting with an acute coronary syndrome, and the combination should not be prescribed routinely to prevent cardiovascular disease.
Read more on Cochrane (Australasian Centre) website
New antiplatelet drugs for acute coronary syndrome | Issue 6 | Volume 37 | Australian Prescriber
Ticagrelor and prasugrel are antiplatelet drugs that are alternatives to clopidogrel in acute coronary syndrome. Their advantages include reduced rates of...
Read more on Australian Prescriber website
New antiplatelet drugs | Issue 6 | Volume 37 | Australian Prescriber
Dentists should be familiar with clopidogrel, which is commonly used in combination with aspirin following placement of coronary stents to prevent coronary...
Read more on Australian Prescriber website
Antiplatelet agents and anticoagulants for hypertension | Cochrane
Daily aspirin reduces the incidence of heart attacks to a small degree, but increases the incidence of major bleeding events to a similar degree in patients treated for high blood pressure who have not had a prior stroke or heart attack. In patients with high blood pressure who have had a stroke or heart attack, the benefits of daily low-dose aspirin outweigh the harms. There is no evidence of benefit for antithrombotic therapy with warfarin alone or in combination with aspirin in patients with high blood pressure. The benefits and harms of the newer drugs glycoprotein IIb/IIIa inhibitors, clopidogrel, prasugrel, ticagrelor and oral antithrombotic agents such as dabigatran and rivaroxaban for patients with high blood pressure have not been studied in clinical trials.
Read more on Cochrane (Australasian Centre) website
Pharmacological treatment for Buerger's disease | Cochrane
Buerger's disease is characterized by recurring progressive inflammation and clotting in small and medium arteries and veins of the hands and feet. Its cause is unknown, but it is most common in men with a history of tobacco use. It is responsible for ulcers and extreme pain in the limbs of young smokers. In many cases, mainly in patients with the most severe form, there is no possibility of improving the condition with surgery, and therefore, drugs (pharmacological agents) are used. These can be pharmacological agents, such as cilostazol, clopidogrel, and pentoxifylline, or medicine derivatives of prostacyclin and prostaglandin, which redirect blood flow and improve the circulation in affected areas, and theoretically, help to heal ulcers and relieve rest pain. This review assessed the effectiveness of pharmacological agents in the treatment of patients with Buerger's disease.
Read more on Cochrane (Australasian Centre) website
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients | Cochrane
Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients
Read more on Cochrane (Australasian Centre) website
Antiplatelet agents for preventing failure of peripheral arterial grafts | Cochrane
Symptomatic peripheral arterial disease in people with atherosclerosis can present as intermittent claudication, disabling pain on walking, or as critical limb ischaemia with pain at rest, ulceration, gangrene and the risk of losing a leg. One treatment option is to implant a graft or makeshift blood vessel to bypass a blockage in the main artery of the thigh. Using a section of the vein from the patient's leg is often better than artificial or prosthetic materials such as Dacron or polytetrafluoroethylene, which take up platelets that could lead to clotting that could block the graft. Other factors affecting the patency of the graft (how long the bypass remains open) include length of the bypass, site where the graft connects to the existing artery and blood flow out of the graft. Stenosis (narrowing) of the graft most frequently occurs at the surgical connections because of hyperplasia, or an increase in the number of smooth muscle cells, into the inner layer of the vessel, often followed by the formation of a thrombosis (clot) at the stenotic site.
Read more on Cochrane (Australasian Centre) website
Medical adjuvant treatment to increase the patency of arteriovenous fistulae and grafts used for renal dialysis | Cochrane
Read more on Cochrane (Australasian Centre) website
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial treatment of acute coronary syndromes | Cochrane
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial treatment of acute coronary syndromes
Read more on Cochrane (Australasian Centre) website
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in patients with type 2 diabetes mellitus | Cochrane
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in patients with type 2 diabetes mellitus
Read more on Cochrane (Australasian Centre) website
